Teva Pharmaceutical Industries Limited (TEVJF)
OTCMKTS · Delayed Price · Currency is USD
28.36
0.00 (0.00%)
At close: Jan 26, 2026
TEVJF Revenue
In the year 2025, Teva Pharmaceutical Industries had annual revenue of $17.26B with 4.32% growth. Teva Pharmaceutical Industries had revenue of $4.71B in the quarter ending December 31, 2025, with 11.40% growth.
Revenue
17.26B
Revenue Growth
+4.32%
P/S Ratio
2.32
Revenue / Employee
539.18K
Employees
37,000
Market Cap
40.02B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 17.26B | 714.00M | 4.32% |
| Dec 31, 2024 | 16.54B | 698.00M | 4.40% |
| Dec 31, 2023 | 15.85B | 921.00M | 6.17% |
| Dec 31, 2022 | 14.93B | -953.00M | -6.00% |
| Dec 31, 2021 | 15.88B | -781.00M | -4.69% |
| Dec 31, 2020 | 16.66B | -228.00M | -1.35% |
| Dec 31, 2019 | 16.89B | -1.38B | -7.57% |
| Dec 31, 2018 | 18.27B | -3.58B | -16.39% |
| Dec 31, 2017 | 21.85B | -50.00M | -0.23% |
| Dec 31, 2016 | 21.90B | 2.25B | 11.45% |
| Dec 31, 2015 | 19.65B | -620.00M | -3.06% |
| Dec 31, 2014 | 20.27B | -42.00M | -0.21% |
| Dec 31, 2013 | 20.31B | -3.00M | -0.01% |
| Dec 31, 2012 | 20.32B | 2.01B | 10.95% |
| Dec 31, 2011 | 18.31B | 2.19B | 13.59% |
| Dec 31, 2010 | 16.12B | 2.22B | 15.99% |
| Dec 31, 2009 | 13.90B | 2.81B | 25.39% |
| Dec 31, 2008 | 11.09B | 1.68B | 17.83% |
| Dec 31, 2007 | 9.41B | 1.00B | 11.89% |
| Dec 31, 2006 | 8.41B | 3.16B | 60.15% |
| Dec 31, 2005 | 5.25B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sofgen Pharma | 423.75M |
| Jushi Holdings | 260.43M |
| Glass House Brands | 196.17M |
| MariMed | 157.38M |
| Elite Pharmaceuticals | 122.89M |
| Earth Science Tech | 33.84M |
| Radnostix | 14.07M |
| Healthy Extracts | 3.59M |
Teva Pharmaceutical Industries News
- 12 days ago - Novo sued for working with Teva to delay generic Victoza - Seeking Alpha
- 14 days ago - FINANCIAL CONSULATE, INC Buys 270 Shares of Teva Pharmaceutical Industries Ltd (TEVA) - GuruFocus
- 15 days ago - Tema Heart & Health ETF Buys 9,762 Shares of Teva Pharmaceutical Industries Ltd (TEVA) - GuruFocus
- 15 days ago - ESGD, SPOT, SE, TEVA: Large Outflows Detected at ETF - Nasdaq
- 15 days ago - Independence Bank of Kentucky Buys 66 Shares of Teva Pharmaceutical Industries Ltd (TEVA) - GuruFocus
- 22 days ago - Teva (TEVA) Gains FDA Approval for Ajovy in Pediatric Migraine Treatment - GuruFocus
- 22 days ago - AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine - GlobeNewsWire
- 22 days ago - Teva Is No Longer A Turnaround Story, It's A Growth One - Seeking Alpha